Takeda hangs alogliptin hopes on CV safety as EC approval secured
This article was originally published in Scrip
Executive Summary
The European Commission has approved a fifth dipeptidyl peptidase IV (DPP-4) inhibitor – Takeda's Vipidia (alogliptin). The approval prompts questions about how Takeda intends to position the product in a crowded market place, and what bearing it may have on earlier speculation that Takeda might acquire Furiex Pharmaceuticals, to which it pays milestones on alogliptin's progress and royalties on sales.